Rallybio Co. (NASDAQ:RLYB – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $12.20.
Several research firms recently weighed in on RLYB. Wedbush cut their price objective on Rallybio from $13.00 to $11.00 and set an “outperform” rating on the stock in a report on Thursday, April 11th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Rallybio in a research report on Friday, May 10th. JPMorgan Chase & Co. lowered Rallybio from an “overweight” rating to a “neutral” rating in a research report on Wednesday, May 15th. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 target price on shares of Rallybio in a research report on Thursday, April 18th. Finally, Jefferies Financial Group lowered Rallybio from a “buy” rating to a “hold” rating in a research report on Wednesday, February 7th.
Check Out Our Latest Research Report on RLYB
Hedge Funds Weigh In On Rallybio
Rallybio Stock Performance
Shares of RLYB stock opened at $1.61 on Friday. Rallybio has a fifty-two week low of $1.23 and a fifty-two week high of $9.14. The company has a market cap of $66.73 million, a PE ratio of -0.86 and a beta of -1.63. The stock’s fifty day moving average price is $1.76 and its two-hundred day moving average price is $2.01.
Rallybio (NASDAQ:RLYB – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.03. On average, equities analysts predict that Rallybio will post -1.42 EPS for the current fiscal year.
About Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.
Featured Stories
- Five stocks we like better than Rallybio
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- What is a Short Call Butterfly Spread? Explanation with Examples
- When to Sell a Stock for Profit or Loss
- First Quarter Wrap-Up Reveals Retail’s Shifting Sands
- NYSE Stocks Give Investors a Variety of Quality Options
- Williams-Sonoma Stock Forecast to Hit $500? Here’s How
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.